| Clinical trials of IL-12/IL-23 inhibitors in inflammatory bowel disease A Almradi, J Hanzel, R Sedano, CE Parker, BG Feagan, C Ma, V Jairath BioDrugs 34, 713-721, 2020 | 79 | 2020 |
| Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy U Kopylov, J Hanzel, C Liefferinckx, D De Marco, N Imperatore, N Plevris, ... Alimentary pharmacology & therapeutics 52 (1), 135-142, 2020 | 62 | 2020 |
| Success and safety of high infliximab trough levels in inflammatory bowel disease D Drobne, T Kurent, S Golob, P Svegl, P Rajar, S Terzic, M Kozelj, ... Scandinavian journal of gastroenterology 53 (8), 940-946, 2018 | 46 | 2018 |
| Anti-interleukin-23 agents for the treatment of ulcerative colitis J Hanžel, GR D’Haens Expert opinion on biological therapy 20 (4), 399-406, 2020 | 45 | 2020 |
| Peak concentrations of ustekinumab after intravenous induction therapy identify patients with Crohn’s disease likely to achieve endoscopic and biochemical remission J Hanžel, J Zdovc, T Kurent, N Sever, K Javornik, K Tuta, M Koželj, ... Clinical Gastroenterology and Hepatology 19 (1), 111-118. e10, 2021 | 42 | 2021 |
| Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease D Drobne, T Kurent, S Golob, P Švegl, P Rajar, J Hanžel, M Koželj, ... Alimentary Pharmacology & Therapeutics 49 (7), 880-889, 2019 | 41 | 2019 |
| Seznam ugotovljenih ptic Slovenije s pregledom redkih vrst/The list of birds of Slovenia with an overview of rare species J Hanžel, D Šere Acrocephalus 32 (150-151), 143-203, 2011 | 40 | 2011 |
| CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease C Ma, J Hanzel, R Panaccione, WJ Sandborn, GR D’Haens, V Ahuja, ... Gastroenterology 163 (4), 950-964, 2022 | 38 | 2022 |
| Vedolizumab and extraintestinal manifestations in inflammatory bowel disease J Hanzel, C Ma, NV Casteele, R Khanna, V Jairath, BG Feagan Drugs 81 (3), 333-347, 2021 | 29 | 2021 |
| Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis J Hanzel, LH Bukkems, KB Gecse, GR D’Haens, RAA Mathôt Alimentary Pharmacology & Therapeutics 54 (10), 1309-1319, 2021 | 28 | 2021 |
| Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease J Hanžel, N Sever, I Ferkolj, B Štabuc, N Smrekar, T Kurent, M Koželj, ... United European Gastroenterology Journal 7 (6), 741-749, 2019 | 28 | 2019 |
| Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases A Volkers, T Straatmijer, M Duijvestein, A Sales, A Levran, F van Schaik, ... Alimentary pharmacology & therapeutics 56 (6), 1044-1054, 2022 | 26 | 2022 |
| Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study J Hanzel, JM Jansen, RWF Ter Steege, KB Gecse, GR D’Haens Inflammatory bowel diseases 28 (4), 495-501, 2022 | 26 | 2022 |
| Dose optimisation for loss of response to Vedolizumab—pharmacokinetics and immune mechanisms B Ungar, K Malickova, J Hanžel, M Abu Arisha, S Paul, C Rocha, ... Journal of Crohn's and Colitis 15 (10), 1707-1719, 2021 | 26 | 2021 |
| Emerging therapies for ulcerative colitis J Hanzel, MS Hulshoff, J Grootjans, G D’Haens Expert Review of Clinical Immunology 18 (5), 513-524, 2022 | 25 | 2022 |
| Managing inflammatory bowel disease during COVID-19: summary of recommendations from gastrointestinal societies J Hanzel, C Ma, JK Marshall, BG Feagan, V Jairath Clinical Gastroenterology and Hepatology 18 (9), 2143-2146, 2020 | 24 | 2020 |
| Redke vrste ptic v sloveniji v letu 2013–Poročilo Nacionalne komisije za redkosti/Rare birds in Slovenia in 2013–Slovenian Rarities Committee's Report J Hanžel Acrocephalus 35 (160-161), 59-72, 2013 | 22 | 2013 |
| Responsiveness of magnetic resonance enterography indices for evaluation of luminal disease activity in Crohn’s disease J Hanžel, V Jairath, C Ma, L Guizzetti, G Zou, CS Santillan, SA Taylor, ... Clinical Gastroenterology and Hepatology 20 (11), 2598-2606, 2022 | 19 | 2022 |
| Pharmacokinetic-pharmacodynamic model of vedolizumab for targeting endoscopic remission in patients with Crohn disease: Posthoc Analysis of the LOVE-CD Study J Hanzel, E Dreesen, S Vermeire, M Löwenberg, F Hoentjen, P Bossuyt, ... Inflammatory bowel diseases 28 (5), 689-699, 2022 | 17 | 2022 |
| Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn’s disease J Hanžel, M Koželj, AŠ Hlastec, T Kurent, N Sever, J Zdovc, N Smrekar, ... European Journal of Gastroenterology & Hepatology 33 (1S), e831-e836, 2021 | 14 | 2021 |
